Protox Announces PRX302 Data to Be Presented at ASCO Sponsored Prostate Cancer Symposium

VANCOUVER, British Columbia, Feb. 23, 2007 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V:PRX) today  announced that additional pre-clinical efficacy and safety data on PRX302, a  novel pore-forming targeted toxin, will be presented this week at the Prostate  Cancer Symposium, a gathering sponsored by the American Society of Clinical  Oncology (ASCO).      

Sam Denmeade, M.D., from Johns Hopkins University, will present the data  on Saturday, February 24, 2007. The presentation, entitled "A Prostate  Specific Antigen (PSA) Activated Channel-forming Toxin as Therapy for Prostate  Cancer" supports PRX302's targeting efficiency in treating prostate-related  diseases as well as its safety profile. The symposium takes place at the  Gaylord Palms Resort and Convention Center in Orlando, Florida. Co-authors of  this presentation include M. Rosen, N. Merchant, J.T. Isaacs, J.T. Buckley and  S.A. Williams.      

PRX302 is rationally designed to kill prostate cancer and hyperplastic  cells that over-produce the enzyme prostate specific antigen (PSA). These data  suggest that PRX302 is ideally suited to treat diseases of the prostate where  the goal is to ablate prostate cancer or hyperplastic tissues without damaging  adjacent tissue such as the urinary bladder, urethra, rectum or seminal  vesicles.      

Based in part on the encouraging preclinical efficacy and safety data to  be presented by Dr. Denmeade, Protox plans to commence a Phase I clinical  trial of PRX302 for the treatment of benign prostatic hyperplasia (BPH) in Q2  of 2007. A Phase 1 trial of PRX302 in patients with locally recurrent prostate  cancer after definitive radiation therapy is currently underway. Interim data  from the first human clinical trial (released in January 2007) indicate that  PRX302 is safe and well tolerated and shows encouraging signs of therapeutic  activity.   

About PRX302   

PRX302 is the lead drug in the company's PORxin(TM) technology platform.  PORxin drugs are pro-drugs that are activated by specific proteases produced  at elevated levels on the surface of target cells. PRX302 has been generated  by engineering the naturally occurring toxin proaerolysin to create a potent  anti-cancer agent with a distinct mode of action. The drug has been engineered  so that it is activated by prostate-specific antigen (PSA), an enzyme that is  overproduced in patients suffering from prostate cancer and enlarged prostate  (benign prostatic hyperplasia or BPH). Once activated, the drug punches holes  in the cells causing the contents to leak out and ultimately cell death.   

About Protox   

Protox Therapeutics is a leader in advancing novel, targeted protein  toxin therapeutics for treatment of cancer and other proliferative diseases.  The company is actively developing two distinct but complementary platforms,  INxin(TM) and PORxin, and currently has three clinical programs in  development. A Phase IIa clinical trial into the use of PRX321 (INxin) for the  treatment of primary brain cancer has been completed and the drug has received  Fast Track Designation and Orphan Drug Status from the US FDA. In addition, a  Phase I trial has been completed for PRX321 to treat patients with renal cell  carcinoma and non-small cell lung cancer. Patient enrolment is underway for a  Phase I clinical study into the use of PRX302 (PORxin) to treat localized  prostate cancer. PRX302 has also been approved by Health Canada to commence a  Phase I clinical study for the treatment of benign prostatic hyperplasia.   

NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS  RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE  ADEQUACY OR ACCURACY OF THIS RELEASE.   

Certain statements included in this press release may be considered  forward-looking. Such statements involve known and unknown risks,  uncertainties and other factors that may cause actual results, performance or  achievements to be materially different from those implied by such statements,  and therefore these statements should not be read as guarantees of future  performance or results. All forward-looking statements are based on Protox'  current beliefs as well as assumptions made by and information currently  available to Protox and relate to, among other things, anticipated financial  performance, business prospects, strategies, regulatory developments, market  acceptance and future commitments. Readers are cautioned not to place undue  reliance on these forward-looking statements, which speak only as of the date  of this press release. Due to risks and uncertainties, including the risks and  uncertainties identified by Protox in its public securities filings; actual  events may differ materially from current expectations. Protox disclaims any  intention or obligation to update or revise any forward-looking statements,  whether as a result of new information, future events or otherwise.   

    

-30-   

/For further information: James Beesley, Director, Investor Relations,  Protox Therapeutics, (604) 688-0199, jbeesley@protoxtherapeutics.com; Michael  Moore, Investor Relations, Equicom Group, (416) 815-0700 x 241,  mmoore@equicomgroup.com

   

 

 

Posted: February 2007

View comments

Hide
(web1)